PT - JOURNAL ARTICLE AU - Dang, Qi AU - Miao, Rui AU - Liang, Yong TI - COVID-19 In Shang Hai: It is Worth Learning from the Successful Experience in Preventing and Controlling the Overseas Epidemic Situation AID - 10.1101/2020.05.13.20100164 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.13.20100164 4099 - http://medrxiv.org/content/early/2020/05/16/2020.05.13.20100164.short 4100 - http://medrxiv.org/content/early/2020/05/16/2020.05.13.20100164.full AB - COVID-19 first appeared in Wuhan, Hubei Province, China in late December 2019 and spread rapidly in China. Currently, the spread of local epidemics has been basically blocked. The import of overseas epidemics has become the main form of growth in China’s new epidemic. As an important international transportation hub in China, Shanghai is one of the regions with the highest risk of imported cases abroad. Due to imported of overseas cases are affected by the international epidemic trend. The traditional infectious disease model is difficult to accurately predict the cumulative trend of cumulative cases in the Shanghai areas. It is also difficult to accurately evaluate the effectiveness of the international traffic blockade. In this situation, this study takes Shanghai as an example to propose a new type of infectious disease prediction model. The model first uses the sparse graph model to analyze the international epidemic spread network to find countries and regions related to Shanghai. Next, multiple regression models were used to fit the existing COV-19 growth data in Shanghai. Finally, the model can predict the growth curve of Shanghai’s epidemic without blocking traffic. The results show that the control measures taken by Shanghai are very effective. At present, more and more countries and regions will face the current situation in Shanghai. We recommend that other countries and regions learn from Shanghai’s successful experience in preventing overseas imports in order to fully prepare for epidemic prevention and control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the Macau Science and Technology Development Funds Grands No.003/2016/AFJ and No.0055/2018/A2 from the Macau Special Administrative Region of the People’s Republic of China.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in this article comes from the Johns Hopkins University Repository, mainly from January 19 to April 19, 2020, the number of daily diagnoses in various countries and regions around the world.